1. Basaria S. Male hypogonadism. Lancet. 2014;383(9924):1250-1263. [DOI:10.1016/S0140-6736(13)61126-5] [PMID]

2. Kumar P, Kumar N, Thakur DS, Patidar A. Male hypogonadism: symptoms and treatment. J Adv Pharm Technol Res. 2010;1(3):297-301. [DOI:10.4103/0110-5558.72420] [PMID] []

3. Pivonello R, Menafra D, Riccio E, Garifalos F, Mazzella M, De Angelis C, et al. Metabolic disorders and male hypogonadotropic hypogonadism. Front Endocrinol (Lausanne). 2019;10:345. [DOI:10.3389/fendo.2019.00345] [PMID] []

4. Rey RA, Grinspon RP, Gottlieb S, Pasqualini T, Knoblovits P, Aszpis S, et al. Male hypogonadism: an extended classification based on a developmental, endocrine physiology-based approach. Andrology. 2013;1(1):3-16. [DOI:10.1111/j.2047-2927.2012.00008.x] [PMID]

5. BUSCH W. Die morphologie der sella turcica und ihre beziehungen zur hypophyse [Morphology of sella turcica and its relation to the pituitary gland]. Virchows Arch Pathol Anat Physiol Klin Med. 1951;320(5):437-458 (German). [DOI:10.1007/BF00957474] [PMID]

6. Lenz AM, Root AW. Empty sella syndrome. Pediatr Endocrinol Rev. 2012;9(4):710-715.

7. Ucciferro P, Anastasopoulou C. Empty sella syndrome. [Updated 2023 Oct 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/sites/books/NBK541002/

8. De Marinis L, Bonadonna S, Bianchi A, Maira G, Giustina A. Primary empty sella. J Clin Endocrinol Metab. 2005;90(9):5471-5477. [DOI:10.1210/jc.2005-0288] [PMID]

9. Fink J, Schoenfeld BJ, Hackney AC, Maekawa T, Horie S. Human chorionic gonadotropin treatment: a viable option for management of secondary hypogonadism and male infertility. Expert Rev Endocrinol Metab. 2021;16(1):1-8. [DOI:10.1080/17446651.2021.1863783] [PMID]

10. La Vignera S, Condorelli RA, Cimino L, Russo GI, Morgia G, Calogero AE. Late-onset hypogonadism: the advantages of treatment with human chorionic gonadotropin rather than testosterone. Aging Male. 2016;19(1):34-39. [DOI:10.3109/13685538.2015.1092021] [PMID]

11. Crosnoe LE, Grober E, Ohl D, Kim ED. Exogenous testosterone: a preventable cause of male infertility. Transl Androl Urol. 2013;2(2):106-113.

12. Corona G, Goulis DG, Huhtaniemi I, Zitzmann M, Toppari J, Forti G, et al. European academy of andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: Endorsing organization: european society of endocrinology. Andrology. 2020;8(5):970-987. [DOI:10.1111/andr.12770] [PMID]

13. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag. 2009;5(3):427-448. [DOI:10.2147/TCRM.S3025] [PMID] []

14. La Vignera S, Condorelli RA, Duca Y, Mongioi LM, Cannarella R, Giacone F, et al. FSH therapy for idiopathic male infertility: four schemes are better than one. Aging Male. 2020;23(5):750-755. [DOI:10.1080/13685538.2019.1590696] [PMID]

15. Boyce MJ, Baisley KJ, Clark EV, Warrington SJ. Are published normal ranges of serum testosterone too high? Results of a cross-sectional survey of serum testosterone and luteinizing hormone in healthy men. BJU Int. 2004;94(6):881-885. [DOI:10.1111/j.1464-410X.2004.05051.x] [PMID]

16. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762-769. [DOI:10.1111/j.1742-1241.2006.00992.x] [PMID] []

17. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724-73. [DOI:10.1210/jcem.86.2.7219] [PMID]

18. McLachlan M, Williams E, Doyle F. Applied anatomy of the pituitary gland and fossa. A radiological and histopathological study based on 50 necropsies. Brit J Radiol. 1968; 41(490):782-788. [DOI:10.1259/0007-1285-41-490-782]

19. Auer MK, Stieg MR, Crispin A, Sievers C, Stalla GK, Kopczak A. Primary empty sella syndrome and the prevalence of hormonal dysregulation. Dtsch Arztebl Int. 2018;115(7):99-105 (German). [DOI:10.3238/arztebl.2018.0099] []

20. Chiloiro S, Giampietro A, Bianchi A, Tartaglione T, Capobianco A, Anile C, et al. Diagnosis of endocrine disease: primary empty sella: a comprehensive review. Eur J Endocrinol. 2017;177(6): 275-285. [DOI:10.1530/EJE-17-0505] [PMID]

21. Kumar K, Khalid M, Fadhil A, Lamba P, Basha SA, Ibrahim SAEZM. Empty sella syndrome: A case report and literature review. Neurosci Med. 2015; 6(1):42-45. [DOI:10.4236/nm.2015.61007]

22. Rani PR, Maheshwari R, Reddy TS, Prasad NR, Reddy PA. Study of prevalence of endocrine abnormalities in primary empty sella. Indian J Endocrinol Metab. 2013;17(Suppl 1):S125-S126. [DOI:10.4103/2230-8210.119527] [PMID] []

23. Ghatnatti V, Sarma D, Saikia U. Empty sella syndrome - beyond being an incidental finding. Indian J Endocrinol Metab. 2012;16(Suppl 2):S321-S323. [DOI:10.4103/2230-8210.104075] [PMID] []

24. Stelmachowska-Banaś M, Czajka-Oraniec I, Zgliczyński W. Clinical and hormonal assessment of patients with empty sella on MRI. Postępy Nauk Medycznych. 2014;23(12):814-8 (Polish).

25. Ahamed MAA, Shetty S, Hegde S, Prasannan P. The emptiness within: A case of empty sella syndrome. Cureus. 2022;14(9):e28941. [DOI:10.7759/cureus.28941] [PMID] []

26. Sugerman HJ, Felton WL 3rd, Salvant JB Jr, Sismanis A, Kellum JM. Effects of surgically induced weight loss on idiopathic intracranial hypertension in morbid obesity. Neurology. 1995; 45(9):1655-1659. [DOI:10.1212/WNL.45.9.1655] [PMID]